IL-33 Production by Nasal Epithelial Cells


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 11-003493
    Sponsor Protocol Number: 11-003493

About this study

This research study is being done for people who have asthma and chronic rhinosinusitis, hay fever, or you do not have any sinus disease, asthma or hay fever (control). The aim of the study is to investigate the functions of nasal epithelial cells.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

The inclusion criteria are as follows: 

1) Asthma and CRS:

  • Physician-diagnosed asthma

  • CRS symptoms with lasting longer than 12 weeks

  • A sinus CT scan within the past 24 months with a Lund-Mackay score > 5 (88).

2) Seasonal allergic rhinitis without asthma and CRS:

The clinical diagnosis of allergic rhinitis is established by history, where patients describe the typical seasonal signs of nose itching, sneezing and clear rhinorrhea, and is confirmed with a positive skin test and/or elevated specific serum IgE level for short ragweed antigen. 

Patients with allergic rhinitis will have no history or symptoms of asthma or of CRS, normal lung function, and negative methacholine responsiveness (PC 20 Methacholine >16 mg/ml).

3) Normal: 

The normal controls are healthy individuals with no history of allergy or CRS, normal spirometry, negative methacholine responsiveness (PC 20 Methacholine >16 mg/ml) and negative skin prick test results or negative IgE serum tests to 10 common aeroallergens.

Exclusion criteria for subjects in any group are as follows:

1) received systemic glucocorticoids or high-dose (>1,000 µg budesonide or equivalent/day) inhaled or intranasal glucocorticoids during the past 6 weeks,

2) previous or current smokers (exceeding a 10 pack year history), or

3) a lower or upper airway infection (e.g. “cold”) in the last 4 weeks.  We will also exclude volunteers who have been diagnosed with an immunodeficiency disease or cystic fibrosis. 


Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hirohito Kita, M.D.

Open for enrollment

Contact information:

Kay Bachman R.N., C.C.R.C.



Mayo Clinic Footer